Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Claritev CorporationNYSE: CTEV
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $46.77M (cash outflow) rose 20.3% year over year, ahead of the +8.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 56.4% from the prior quarter. Over 3 fiscal years it compounded at +13.0% a year.
Context
- Capital expenditures amounted to 13.4% of revenue in FY2025, up 0.7 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.3% holds above the trailing-twelve-month pace of +8.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (129.6M) USD
- Year-over-year change
- -9.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.6M) | -9.7% |
| FY2024 | 2024-12-31 | (118.12M) | -8.5% |
| FY2023 | 2023-12-31 | (108.85M) | -21.3% |
| FY2022 | 2022-12-31 | (89.74M) | -6.1% |
| FY2021 | 2021-12-31 | (84.59M) | — |
Capital Expenditures vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 capital expenditures of $137.5M is the largest of the 11 companies compared; the peer median is $5.58M.
- Its year-over-year change of +8.7% is the 6th highest of 11, against a peer median of -8.9%.
- Capital expenditures amounts to 14.0% of revenue for CTEV, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $137.5M | +8.7% | +13.0% | 14.0% |
| LTM Mar 2026 | $81.57M | -36.2% | +26.6% | 5.0% | |
| LTM Mar 2026 | $38.69M | -31.1% | -60.0% | 4.9% | |
| LTM Mar 2026 | $31.9M | +13.4% | -3.9% | 1.7% | |
| LTM Mar 2026 | $10.92M | -54.1% | -20.7% | 1.9% | |
| LTM Mar 2026 | $9.17M | +175.1% | -9.6% | 4.2% | |
| LTM Sep 2026 | $6.32M | +72.9% | -43.9% | 2.4% | |
| LTM Mar 2026 | $4.85M | -59.7% | +60.6% | 5.6% | |
| LTM Mar 2026 | $1.12M | +73.4% | -14.9% | 0.3% | |
| LTM Mar 2026 | $1.09M | -93.8% | -64.4% | — | |
| LTM Jun 2026 | $334K | +165.1% | +15.3% | 17.5% | |
| Peer median (excluding CTEV) | $5.58M | -8.9% | -12.2% | 4.2% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Depreciation & Amortization | 424.32M | 415.66M | 425.79M | 436.44M | 445.43M |
| Deferred Income Tax | (81.93M) | (114.38M) | (114.06M) | (198.01M) | (128.51M) |
| Stock-Based Compensation | 18.01M | 16.74M | 18.02M | 26.65M | 27.82M |
| Change in Working Capital | (46.68M) | 55.34M | (21.91M) | (13.67M) | (28.87M) |
| Accounts Receivables | (33.83M) | 21M | 4.4M | (13.2M) | (26.57M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.71M | 34.35M | 5.58M | 42.22M | (25.86M) |
| Other Working Capital | (12.85M) | 34.34M | (26.31M) | (42.69M) | 23.57M |
| Other Non-Cash Items | (93.04M) | 571.92M | (44.42M) | 1.5B | 85.73M |
| Operating Cash Flow | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Capital Expenditures | (84.59M) | (89.74M) | (108.85M) | (118.12M) | (129.6M) |
| Acquisitions (Net) | (149.43M) | 0 | (140.94M) | 0 | 0 |
| Purchases of Investments | 0 | (15M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 289K | 0 | 0 | 16M |
| Other Investing Activities | 5.64M | 0 | 0 | 0 | (7.42M) |
| Investing Cash Flow | (228.38M) | (104.45M) | (249.79M) | (118.12M) | (121.02M) |
| Debt Repayment | (10.9M) | (13.28M) | (165.82M) | (28.07M) | 4.72M |
| Common Stock Issued | 0 | 0 | 508K | 0 | 1.74M |
| Common Stock Repurchased | (103.79M) | (100M) | (15.22M) | (10.37M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.79M) | (2.46M) | (465K) | (2.88M) | (4.1M) |
| Financing Cash Flow | (114.68M) | (115.74M) | (180.99M) | (41.32M) | 2.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 61.62M | 152.18M | (259.07M) | (51.82M) | (1.33M) |
| Free Cash Flow | 320.1M | 282.63M | 62.87M | (10.51M) | (12.28M) |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.